EUVIMEDEUVIMED entdecken
Crossref

Comparative Prognostic Value of Mayo 2012 and European‐Modified Mayo 2004 Staging Systems in Systemic AL Amyloidosis With Discordant Risk Classification

Miran Han iD, Jun Ho Yi iD, Sang Eun Yoon, Seokjin Kim iD, Darae Kim, Jin-Oh Choi, Jung Eun Lee iD, Jung-Sun Kim iD, Ju-Hong Min iD, Byoung Joon Kim, Kihyun Kim iD

European Journal of Haematology · 15.11.2026

DOI: 10.1111/ejh.70357 ↗

Kurz gefasst

Fachartikel in der Zeitschrift European Journal of Haematology, online erschienen am 15.11.2026. Verfasst von Miran Han und 10 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Die Arbeit nennt 22 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objectives

The Mayo 2012 and European‐modified Mayo 2004 (European‐modified) staging systems are widely used in systemic light‐chain (AL) amyloidosis, but their comparative prognostic performance in patients with discordant stage classifications remains unclear.

Methods

We retrospectively analyzed 177 patients with systemic AL amyloidosis treated with first‐line bortezomib‐based therapy between January 2020 and March 2025. Patients were classified using both staging systems, and discordance was assessed using predefined stage mapping. Overall survival (OS) was evaluated using Kaplan–Meier analysis, time‐dependent receiver operating characteristic curves, concordance indices, and Cox regression. Hematologic and organ responses were assessed as exploratory outcomes.

Results

Discordant stage classifications were identified in 83 patients (46.9%). In this subgroup, the European‐modified system demonstrated significant separation of OS curves across stages (log‐rank p = 0.0008), identifying Stage IIIB as a particularly high‐risk group with a median OS of 2.9 months. The Mayo 2012 system also significantly stratified OS. At 6 months, the European‐modified system showed a numerically higher time‐dependent AUC than the Mayo 2012 system (0.759 vs. 0.614), although the difference was not statistically significant ( p = 0.092). Similar nonsignificant differences were observed at 12 and 24 months, and differences in Harrell's and Uno's C‐indices were also not statistically significant. Exploratory treatment response analyses were limited by potential selection bias and nonuniform response assessment.

Conclusions

Among patients with discordant stage classifications, the European‐modified system demonstrated significant OS stratification and identified patients at particularly high risk of early mortality. Although it showed numerically higher prognostic discrimination than the Mayo 2012 system, the differences were not statistically significant. These findings suggest potential clinical utility for early risk stratification but require validation in larger independent cohorts.

Schlagwörter

Stichwörter der Autor:innen

biomarkersimmunoglobulin light‐chain amyloidosisprognosissurvival analysis

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Hematology-Oncology, Department of Medicine, Jeonbuk National University Medical School and Hospital, Jeonju, South Korea.
  • Division of Cardiology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Division of Nephrology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Pathology and Translational Genomics, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Neurology, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.

ORCID-Profile: Miran Han, Jun Ho Yi, Seokjin Kim, Jung Eun Lee, Jung-Sun Kim, Ju-Hong Min, Kihyun Kim

Zitieren

APA

Han, M., Yi, J. H., Yoon, S. E., Kim, S., Kim, D., Choi, J. O., Lee, J. E., Kim, J. S., Min, J. H., Kim, B. J., & Kim, K. (2026). Comparative Prognostic Value of Mayo 2012 and European‐Modified Mayo 2004 Staging Systems in Systemic AL Amyloidosis With Discordant Risk Classification. European Journal of Haematology. https://doi.org/10.1111/ejh.70357

Vancouver

Han M, Yi JH, Yoon SE, Kim S, Kim D, Choi JO, et al. Comparative Prognostic Value of Mayo 2012 and European‐Modified Mayo 2004 Staging Systems in Systemic AL Amyloidosis With Discordant Risk Classification. European Journal of Haematology. 2026. doi:10.1111/ejh.70357

BibTeX
@article{Han2026,
  author = {Han, Miran and Yi, Jun Ho and Yoon, Sang Eun and Kim, Seokjin and Kim, Darae and Choi, Jin-Oh and Lee, Jung Eun and Kim, Jung-Sun and Min, Ju-Hong and Kim, Byoung Joon and Kim, Kihyun},
  title = {Comparative Prognostic Value of Mayo 2012 and European‐Modified Mayo 2004 Staging Systems in Systemic AL Amyloidosis With Discordant Risk Classification},
  journal = {European Journal of Haematology},
  year = {2026},
  doi = {10.1111/ejh.70357}
}
Kostenlos starten →